State of the art of radiomic analysis in the clinical management of prostate cancer: A systematic review.
CT
Clinical management
MRI
PET
Prostate cancer
Radiomics
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
28
07
2021
revised:
18
10
2021
accepted:
18
10
2021
pubmed:
22
11
2021
medline:
18
1
2022
entrez:
21
11
2021
Statut:
ppublish
Résumé
We present the current clinical applications of radiomics in the context of prostate cancer (PCa) management. Several online databases for original articles using a combination of the following keywords: "(radiomic or radiomics) AND (prostate cancer or prostate tumour or prostate tumor or prostate neoplasia)" have been searched. The selected papers have been pooled as focus on (i) PCa detection, (ii) assessing the clinical significance of PCa, (iii) biochemical recurrence prediction, (iv) radiation-therapy outcome prediction and treatment efficacy monitoring, (v) metastases detection, (vi) metastases prediction, (vii) prediction of extra-prostatic extension. Seventy-six studies were included for qualitative analyses. Classifiers powered with radiomic features were able to discriminate between healthy tissue and PCa and between low- and high-risk PCa. However, before radiomics can be proposed for clinical use its methods have to be standardized, and these first encouraging results need to be robustly replicated in large and independent cohorts.
Identifiants
pubmed: 34801699
pii: S1040-8428(21)00331-0
doi: 10.1016/j.critrevonc.2021.103544
pii:
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103544Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.